Sciensus

Join us at the British Oncology Pharmacy Association (BOPA) Conference 2026. Where cancer care happens is changing. For oncology pharmacy teams, the challenge is creating capacity and giving patients greater choice without compromising safety, governance

Join us at the World Orphan Drug Congress Europe where our team will share insights into how rare disease companies can navigate European launch, access and commercialisation more effectively. Through discussions on tailored commercial models, early acces

Cancer treatment has changed significantly over the last decade. Alongside advances in medicines, medical technologies are changing how some treatments can be delivered and supported. At Sciensus, we're committed to delivering a variety of cancer treatmen

A patient sits across from you. You tell them a biologic or specialist therapy could help but then you tell them it isn't available through the NHS. NICE approval is built on population-level evidence and cost thresholds, not the person in front of you. T

Sciensus and Portsmouth Hospitals University NHS Trust have completed a year-long project to introduce a fully digital signature process for cancer treatment prescriptions, cutting a process that used to take up to a day and a half down to a few minutes o

Managing a rare metabolic condition takes more than medication and appointments. It takes a monthly delivery you can count on, a plan for the days that don't go as expected and a way to keep doing the ordinary things - work, school, weekends - without tre

+12 percentage point improvement in medication persistence at 12 months when analysing 36,000 patient records. At a glance Sciensus have developed a hybrid digitally enabled patient support programme designed to improve medication adherence and persistenc

Access to orphan medicines is becoming increasingly influenced by global pricing policy. As Most Favoured Nation (MFN) pricing and International Reference Pricing (IRP) become more closely interconnected, pharmaceutical companies are rethinking how they a

Cancer medicines are evolving rapidly. Across cancer, more treatments are moving into targeted, oral and longer-term pathways, giving patients new options and greater flexibility in how their care is delivered. But this shift also changes what success loo

Coopetition can sound like jargon, but the idea is straightforward: providers compete to deliver the best possible service, while recognising that some challenges are bigger than any one organisation. Read the Connected Care Report Why the foundations mat